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Summary  Hepatitis  E  virus  (HEV)  typically  causes  an  acute,  self-limiting  hepatitis  and  is  among
the commonest  cause  of  such  presentations.  Hepatitis  E  viral  infection  is  also  increasingly  reco-
gnized as  a  cause  of  chronic  hepatitis  amongst  the  immunocompromised,  particularly  amongst
solid organ  transplant  recipients.  Chronic  HEV  infection  remains  an  underdiagnosed  disease
and chronic  infection  can  lead  to  rapidly  progressive  liver  ﬁbrosis  and  cirrhosis.  This  review
examines  current  understanding  of  the  HEV.  We  illustrate  typical  clinical  presentations,  mana-
gement strategies  [(based  upon  guidelines  from  both  the  British  Transplant  Society  (BTS)  andviral  hepatitis European  Association  for  the  study  of  liver  (EASL)]  and  outcomes  of  HEV  infection  in  different
cohorts of  patients  by  highlighting  select  transplant  and  non-transplant  patient  cases,  from  one
of the  largest  tertiary  Hepatology  centres  in  Europe.
© 2019  Les  Auteurs.  Publie´  par  Elsevier  Masson  SAS.  Cet  article  est  publie´  en  Open  Access  sous
licence CC  BY  (http://creativecommons.org/licenses/by/4.0/).
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What  is  already  known?Pour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
Hepatitis  E  virus  (HEV)  infection  which  was  traditionally
thought  to  be  a  condition  mainly  affecting  travellers  and
populations  within  developing  nations  is  now  being  increa-
∗ Corresponding author at: University Hospitals Birmingham,
Ofﬁce 6, 2nd ﬂoor Institution of Translational Medicine, United King-
dom.
Adresse e-mail : a.chauhan.1@bham.ac.uk (A. Chauhan).
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2210-7401/© 2019 The Authors. Published by Elsevier Masson SAS. T
creativecommons.org/licenses/by/4.0/).ingly  detected  amongst  Western  cohorts  of  patients.  An
ncrease  in  both  incidence  and  prevalence  in  the  last  decade
as  been  noted  and  immunosuppressed  individuals  such  as
olid  organ  transplant  recipients  are  at  signiﬁcant  risk  of
eveloping  chronic  hepatitis  and  liver  ﬁbrosis.
hat  this  review  adds? of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
e  build  upon  our  current  understanding  about  the  patho-
iology  and  epidemiology  of  this  virus  by  appraising  and
resenting  the  latest  evidence  surrounding  HEV  infection.
e  next  illustrate  clinical  presentation,  management  stra-
his is an open access article under the CC BY license (http://
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egies  and  outcomes  of  HEV  infection  in  different  cohorts
f  patients  using  select  patient  cases  from  a  large  European
ertiary  Hepatology  centre.
ho  will  this  beneﬁt  from  this  review?
his  will  be  of  value  to  all  gastroenterologists  and  hepatolo-
ists  involved  in  the  care  of  patients  presenting  with  acute
epatitis,  as  well  as  those  caring  for  the  chronically  immu-
osuppressed  including  transplant  recipients.  We  highlight
EV  infection  as  an  increasingly  relevant  differential  diag-
osis  in  immunosuppressed  individuals  with  deranged  liver
unction  tests  and  even  in  those  with  suspected  drug  induced
iver  injury.
epatitis E virology
he  virus
epatitis  E  virus  (HEV)  infection  is  estimated  to  be  the  com-
onest  cause  of  acute  hepatitis  in  the  world  [1].  Khuroo  et  al
rst  identiﬁed  HEV  as  an  unknown  non-A,  non-B  virus  during
n  outbreak  of  jaundice  in  the  winter  of  1978—1979  in  Kash-
ir  [2].  Subsequently  a  Russian  army  doctor  provided  the
rst  evidence  of  faeco-oral  transmission  of  this  virus.  During
he  Soviet  occupation  of  Afghanistan  in  the  1980s  to  investi-
ate  the  nature  of  an  outbreak  of  unexplained,  non-A,  non-B
cute  hepatitis  at  a  military  encampment,  he  ingested  poo-
ed  faecal  extract  from  affected  soldiers,  and  subsequently
eveloped  the  illness.  His  serum  contained  particles  that
eacted  with  saved  sera  from  those  previously  diagnosed
ith  the  new  hepatitis,  thus  conﬁrming  faeco-oral  transmis-
ion  of  the  virus  [3].  Others  have  subsequently  emulated  the
rocedure  [4].
HEV  infection  is  in  the  majority  of  patients  a  self-limiting
nfection  causing  a  hepatitis,  which  may  be  accompanied
y  jaundice.  Typical  symptoms  include  anorexia,  malaise,
ausea  and  jaundice;  in  the  immunocompetent  individual,
he  infection  and  symptoms  normally  resolve  spontaneously
ithin  4—6  weeks  and  the  median  incubation  period  bet-
een  infection  and  development  of  symptoms  is  40  days
5].  Although  the  majority  of  patients  who  become  infected
ith  HEV  remain  asymptomatic  [1],  HEV  infection  in  cer-
ain  groups  of  patients  may  cause  more  fulminant  disease
r  progressive  ﬁbrosis.  Those  with  pre-existent  chronic  liver
isease  for  instance  can  develop  acute  on  chronic  liver  fai-
ure;  infection  during  the  third  trimester  of  pregnancy  is
ssociated  with  high  maternal  and  foetal  mortality  [6].  HEV
s  now  increasingly  identiﬁed  as  a  cause  of  chronic  infec-
ion  in  immunocompromised  patients  including  transplant
atients  [7].  The  frequent  and  rapid  rate  of  progression
o  hepatic  ﬁbrosis  and  cirrhosis  in  solid  organ  transplant
ecipients  (with  60%  of  those  infected  developing  chro-
ic  hepatitis  [8]  and  10%  of  all  HEV  infected  transplant
ecipients  progressing  to  cirrhosis  [9]),  who  are  often  on
 complex  regime  of  immuno-suppression,  makes  timely
ecognition  and  prompt  treatment  particularly  importantPour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  p
representative  case  histories.  Clin  Res  Hepatol  Gastroenter
10].
There  are  7  genotypes  (G1—7)  of  this  hepatotropic  RNA
irus  [11];  G1  to  G4  and  G7  are  capable  of  human  infection
12];  genotypes  5  and  6  only  infect  animals  [13].  G1  and  G2
n
t
H
t PRESS
A.  Chauhan  et  al.
re  exclusively  human  pathogens  and  responsible  for  water-
orne  outbreaks  in  developing  countries  [5]; G3  and  G4  are
nzootic  in  swine  [14].
The  genus  Sus,  which  includes  pigs  reared  for  human
onsumption  as  well  as  other  species  including  wild  boar,
rovides  a  large  reservoir  for  G3  and  G4  [14].  HEV  causes  no
orbidity  in  pigs,  and  although  effective  porcine  vaccines
xist,  grounds  for  their  use  in  pigs  (to  effectively  reduce  the
eservoir  for  human  infection)  against  HEV  are  thus  weak
15]. This  remains  an  important  consideration  as  foodborne
oonosis  represents  the  commonest  mode  of  HEV  infection
G3  and  G4)  in  the  Western  world  [15].  Infected  porcine
eat  infects  humans  as  end  line  hosts  but  human-to-human
ransmission  of  G3  and  G4  appears  restricted  to  blood  trans-
usion  and  organ  transplantation  [14].
pidemiology and transmission
EV  infection  is  a  signiﬁcant  public  health  problem:  the
orld  Health  Organisation  estimates  that  there  are  about  20
illion  HEV  infections  worldwide  per  year  [5]  with  the  majo-
ity  of  the  disease  burden  being  secondary  to  HEV  G1/G2
nfection  [20]  HEV  infection  causes  a clinically  identiﬁable
cute  liver  injury  in  3.5  million  and  approximately  56,000
eaths  (2800  per  1,000,000  infections)  [21,22].
G1  and  G2  HEV  are  endemic  in  certain  developing  coun-
ries  and  associated  with  water-borne  outbreaks.  G1  is  found
n  Asia  and  Africa;  G2  is  less  common  and  found  in  Mexico
nd  Africa  [7]  (Fig.  1).  The  majority  of  HEV  infections  in  the
eveloping  world  are  thus  due  to  HEV  G1  or  G2  but  the  true
urden  of  disease  is  not  known  [5,7].  The  genotypes  respon-
ible  for  tropical  or  endemic  HEV  (G1  and  G2)  mainly  affect
ounger  people  compared  to  the  HEV  G3  infections  which  are
redominantly  found  in  middle  aged  men  [18]. Outbreaks  in
he  West  remain  relatively  rare  but  have  been  reported  in
nstances  of  common-source  foodborne  outbreaks  [23].
HEV  G3  and  G4  are  the  zoonotic  HEV  genotypes  [15];  G4
s  mainly  found  in  Asia  [7]. HEV  G3  remains  the  dominant
enotype  responsible  for  autochthonous  (locally  acquired)
ransmission  in  the  West  [5]. There  is  marked  variability
mongst  reported  Anti-HEV  G3  seroprevalence  in  mainland
urope,  ranging  from  0.6%  to  52%  [24]  and  between  3—16%
n  the  UK  [5].  Considerable  geographical  variability  is  obser-
ed  in  HEV  G3  infection  within  countries,  for  example  in
rance,  there  is  a  much  higher  reported  seroprevalence
n  the  southwest,  southeast  and  northeast  of  the  country
5,25].  Contaminated  food  stuffs  are  thought  responsible  for
his  regional  variation:  The  mechanism  of  transmission  of
EV  G3  and  G4  is  predominantly  food  or  blood  products  [1].
Although  de  novo  cases  of  HEV  are  rarely  reported  in
he  United  States  (US),  a  2009  study  placed  the  seropre-
alence  of  anti-HEV  IgG  in  the  US  population  at  21%  [26];
eat  consumption  was  a signiﬁcant  risk  factor  for  seroposi-
ivity.  Guidelines  published  by  the  British  Transplant  Society
BTS)  estimate  that  1  in  2500  blood  donations  are  HEV  RNA
ositive  and  the  UK  Advisory  Committee  for  the  Safety  of
lood,  Tissues  and  Organs  thus  recommend  universal  scree-resentations  of  Hepatitis  E:  A  clinical  review  with
ol  (2019),  https://doi.org/10.1016/j.clinre.2019.01.005
ing  for  all  blood  components  for  HEV  (with  particular  care
aken  not  to  transfuse  some  immunosuppressed  groups  with
EV  +  bloods)  [27].  It  is  important  to  note  that  HEV  infec-
ed  donor  blood  is  on  the  whole  rare  and  that  even  infected
ARTICLE IN PRESSModele +CLINRE-1232; No. of Pages 9
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Figure  1  A.  Age-standardised  disability-adjusted  life-year  rates  (per  100,000  per  year)  attributable  to  hepatitis  E  virus  (2013,
by country).  Adapted  from  data  provided  in  Stanaway  et  al.  [22].  B  Dominant  genotypes  of  clinical  cases  of  hepatits  E  infection.
Adapted from  Kamar  et  al  [1].
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fFigure  2  Graph  demonstrating  how  HEV  viral  load  varies  with
from Dalton  et  al.  [38]).
blood  tends  to  contain  low  levels  of  virus;  this  is  in  most
cases  insufﬁcient  to  cause  recipient  infection  [14].  Tedder
et  al  demonstrated  that  the  lowest  viral  dose  that  resulted
in  infection  was  2  ×  104 IU  and  that  55%  of  all  blood  com-
ponents  containing  this  dose  or  more  transmitted  infection
[14]  but  go  on  to  suggest  that  for  the  vast  majority  of  solid
organ  transplant  recipients,  dietary  risks  far  exceed  the  risks
from  transfusion  from  unscreened  donors  [14], a  large  Cana-Pour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
dian  study  further  conﬁrmed  that  the  risk  of  acquiring  HEV
through  an  infected  blood  donation  is  low  [28].  The  biggest
risk  factors  for  acquiring  HEV  in  the  West  are  thus  being  on
haemodialysis  [29],  consumption  of  infected  meat  [30,31]
D
H
vpect  to  development  of  jaundice  and  seroconversion  (adapted
r  for  workers  who  come  into  contact  with  swine  regularly
32,33].  Direct  transmission  from  consumption  of  infected
ild  boar  [17], pig  [34]  and  deer  [35]  meat  has  been  clearly
emonstrated  and  both  the  BTS  and  EASL  recommend  advi-
ing  all  solid  organ  transplant  recipients  regarding  the  risk
rom  undercooked  meat  particularly  pork  [36,37]. of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
iagnostic testing
EV  can  be  detected  by  either  directly  demonstrating  the
iral  genome  in  biological  samples  such  as  in  stool  or  blood,
ARTICLE IN PRESSModele +CLINRE-1232; No. of Pages 9
4  A.  Chauhan  et  al.
Table  1  Summary  of  known  relative  virulence,  species  affected  and  mode  of  transmission  for  different  strains  of  HEV  [5,15—19].
Genotype  Virulence Species  affected Dominant  mode  of  transmission
G1  +++  Humans  Faeco-oral
G2 +++  Humans  Faeco-oral
G3 +  Humans  and  swine Zoonotic  transmission  from  consumption  of  infected
meat  and  via  blood  transfusion  from  affected  donorG4 ++  Humans  and  swine
G5 unknown  Swine No  reported  human  cases
One  reported  case  of  transmission  to  humans  fromG6 unknown  Swine
o
[
o
t
o
y
[
v
d
l
c
a
n
a
a
f
f
l
r
n
w
s
p
f
i
c
s
k
b
f
v
t
a
m
i
a
r
l
C
A
A
s
e
a
s
c
n
p
m
u
o
i
a
d
b
c
t
w
t
t
l
p
m
f
c
m
H
T
T
t
u
i
G
G
m
t
t
a
O
t
A
A
sG7 unknown  Camels
r  indirectly  by  testing  for  HEV-speciﬁc  IgM  or  IgG  antibodies
38].  Anti-HEV  IgM  seropositivity  precedes  the  development
f  IgG,  peaking  at  the  same  time  as  peak  ALT  and  lasting  up
o  5  months  after  the  initial  disease  onset;  IgG  antibodies
n  the  other  hand  appear  after  IgM  but  can  last  beyond  a
ear,  occasionally  disappearing  before  the  one  year  mark
38]  (Fig.  2).
Re-infection  with  HEV  will  result  in  repeated  serocon-
ersions  which  makes  determining  duration  of  infection
ifﬁcult,  thus  estimating  chronicity  of  infection  from  sero-
ogy  alone  is  challenging;  this  is  particularly  an  issue  in
ountries  where  the  virus  is  endemic  [1].  The  predictive
ccuracy  of  positive  IgM  anti-HEV  antibody  assays  in  diag-
osing  HEV  in  low  endemicity  areas  and  in  patients  with
typical  presentations  is  poor  [39].  Additionally,  there  exists
 wide  variability  in  diagnostic  accuracy  between  the  dif-
erent  commercially  available  immunoassays  [40].  A  study
rom  Taiwan  examining  both  IgG  and  IgM  anti-HEV  revea-
ed  that  whilst  most  assays  performed  excellently  with
egards  to  negative  predictive  value  (98.4%-100%),  this  was
ot  however  the  case  with  positive  predictive  value  as  a
ide  intra-test  variability  in  speciﬁcity  (62.9—95.6%)  and
ensitivity  (66.7—93.3%)  was  seen  [41].  Furthermore,  false
ositives  for  HEV  serology  have  been  reported  with  other
orms  of  acute  viral  hepatitis  [42]  and  even  systemic  EBV
nfection  [43].  For  these  reasons,  the  gold  standard  for
onﬁrming  HEV  remains  detecting  the  virus  in  biological
amples  via  polymerase  chain  reaction  (PCR).  Broadly  spea-
ing,  the  virus  is  detectable  in  stool  a  week  before  symptoms
egin  and  remains  detectable  for  up  to  6  weeks,  the  window
or  detection  in  the  serum  is  smaller  [38]. An  undetectable
iral  RNA  load  does  not  necessarily  rule  out  recent  HEV  infec-
ion  as  timely  sample  collection,  early  patient  presentation
nd  local  epidemiology  inﬂuences  the  sensitivity  of  available
olecular  tests  [1].  Direct  viral  detection  is  of  particular
mportance  in  patients  on  immunosuppressive  medications
s  the  seroconversion  process  in  such  a  cohort  is  often  impai-
ed  and  thus  relying  on  antibodies  alone  for  diagnosis  may
ead  to  a  false  negative  results  [44].
linical presentations
cute  hepatitis  in  the  immunocompetent  hostPour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
cute  HEV  infection  (regardless  of  causative  genotype)  is
ilent  and  self-limiting  in  the  vast  majority;  Kamar  at  al
stimate  that  both  in  sporadic  infection  and  outbreaks
symptomatic  individuals  with  HEV  infection  outnumber  the
a
r
T
iinfected  camel  meat/milk
ymptomatic  by  almost  4  to  1  [1]. When  it  does  manifest
linically,  acute  HEV  infection  presents  in  an  identical  man-
er  to  other  viral  hepatitides  including  a  short  non-speciﬁc
rodromal  phase  characterised  by  inﬂuenza-like  symptoms,
yalgia  and  malaise  followed  by  jaundice,  itching  and  dark
rine  [18].  Peak  serum  alanine  transaminase  (ALT)  activity
ccurs  around  6  weeks  after  infection;  the  incubation  per-
od  for  symptomatic  acute  HEV  infection  is  between  three
nd  eight  weeks  [16]. Tropical  and  endemic  variants  of  the
isease  (G1  and  G2)  are  associated  with  a  more  aggressive
iochemical  [18]  and  clinical  phenotype  with  16%  of  those
ontracting  the  virus  exhibiting  signs  of  an  acute  inﬂamma-
ory  hepatitis  [45]  compared  to  only  2%  in  those  infected
ith  G3  or  G4  [46]. Progression  of  acute  HEV  infection
o  fulminant  liver  failure  remains  rare  and  there  are  only
wo  recorded  examples  of  HEV  induced  acute  fulminant  fai-
ure  requiring  emergency  transplantation  [47,48].  Given  the
otential  similarity  in  presentation,  some  authors  recom-
end  testing  all  suspected  cases  of  drug  induced  liver  injury
or  HEV  infection  [49]. Finally,  it  is  worth  noting  that  in  one
entre’s  experience  the  triad  of  bilateral  shoulder  pain  in  a
iddle-aged  male  with  abnormal  LFTs  is  highly  predictive  of
EV  infection  [50].
reatment
he  majority  of  acute  HEV  infections  are  self-limiting  and
hus  do  not  require  treatment  [5,18].  Ribavirin  has  been
sed  to  treat  cases  of  severe  acute  and  ACLF  due  to  HEV
nfection  with  varying  degrees  of  success  in  areas  where
1/G2  infection  are  endemic  [51]. Treatment  of  acute  HEV
3  infection  using  ribavirin  has  also  been  described  [52];
ore  recently  however  cases  of  ribavirin  resistance  and
reatment  failure  have  been  noted,  these  seem  to  relate
o  either  ribavirin  dose  reduction  due  to  side  effects  such
s  anaemia  or  HEV  mutations  (G1634R  mutation  in  the  HEV
RF1  protein)  [5].  In  all  cases,  clear  thresholds  for  the  ini-
iation  of  ribavirin  therapy  remain  undeﬁned.  Table  1
cute  hepatitis  in  the  immunocompromised  host
cute  HEV  in  immunocompromised  patients  generally  pre-
ents  asymptomatically  [53],  if  symptoms  do  occur  these of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
re  non-speciﬁc  and  include  jaundice,  fatigue,  diar-
hoea  and  myalgia.  Predictably,  the  necroinﬂammatory
-cell  mediated  immune  response,  which  accompanies  HEV
nfection,  is  more  aggressive  in  the  immunocompetent
ARTICLE IN PRESSModele +CLINRE-1232; No. of Pages 9
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Figure  3  HEV  infection  drives  the  rapid  development  of  cirrhosis  in  patients  on  immunosuppressive  medication.  Patient  who  had
undergone simultaneous  heart  and  kidney  transplantation  in  2002  and  on  triple  immunosuppression  (mycophenolate  mofetil,  tacro-
limus and  prednisolone)  was  referred  to  liver  medicine  after  having  been  noted  to  have  deranged  liver  function.  The  ﬁrst  noted
elevations in  serum  alanine  aminotransferase  (ALT)  activity  was  recorded  as  94IU/l  which  coincided  with  symptoms  of  malaise,
lethargy and  diarrhoeal  symptoms.  The  referring  team  screened  him  for  liver  disease,  stopped  his  statin  medication  and  presump-
tively treated  him  for  cytomegalovirus  hepatitis.  When  his  liver  biochemistry  failed  to  improve  he  was  referred  and  seen  in  liver
clinic. He  had  established  liver  cirrhosis  with  signiﬁcant  portal  hypertension  with  median  transient  elastography  at  his  index  liver
appointment  >  20  kPa.  He  was  subsequently  found  to  have  a  HEV  load  of  over  2.4  ×  106  IU/mL  with  compatible  serology  (HEV  IgM
and IgG  positive).  Ribavirin  was  initiated  which  resulted  in  a  virological  and  serum  ALT  response.  He  is  now  being  followed  up  as
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detected, to  the  likely  development  of  chronicity  through  to  co
individual.  Thus  whilst  serum  transaminase  activity  in
non-immunosuppressed  individuals  at  presentation  is  often
greater  than  1000  IU/L;  it  is  often  in  the  100—300  IU/L  range
in  the  immunosuppressed  [53].  The  natural  history  of  acute
infection  in  solid  organ  transplant  recipients  suggests  that
speciﬁc  treatment  or  immunosuppressant  modiﬁcation  is  not
always  necessary,  because  a  signiﬁcant  number  will  clear  the
virus  spontaneously  [37].
Treatment
Initial  management  of  acute  HEV  infection  is  suggested  to
be  careful  monitoring  of  HEV  RNA  levels,  serology  and  hepa-
tic  enzyme  activity.  The  BTS  and  EASL  both  advocate  an
approach  of  careful  reduction  in  immunosuppressive  medi-
cation  where  feasible  [36,37],  except  when  HEV  infection  is
associated  with  extrahepatic  manifestations  where  the  BTS
guidelines  recommend  early  treatment  with  ribavirin.  It  is
noteworthy  however  that  a  study  from  Holland  found  that
immunosuppression  reduction  exhibited  greater  efﬁcacy  in
HEV  eradication  than  ribavirin  in  patients  with  extrahepatic
HEV  manifestations  [54].
Acute  hepatitis  in  pregnancy
A  group  of  patients  that  merit  speciﬁc  mention  in  the  con-
text  of  acute  HEV  G1  infection  is  pregnant  women.  Infection
particularly  in  the  third  trimester  is  associated  with  devas-
tating  maternal  and  foetal  outcomes  [5].  A  study  from  India
conﬁrmed  that  outcomes  for  pregnant  patients  with  acute
viral  hepatitis  were  far  poorer  both  for  the  mother  and  foe-Pour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
tus  when  the  infecting  virus  was  HEV  compared  to  hepatitis
B  or  C  [6],  although  the  aetiopathogenesis  behind  this  is
unclear;  the  relative  immunocompromised  state  that  pre-
gnancy  confers  is  likely  culpable  [5].  Treatment  is  primarily
u
[
mThe  time  course  from  the  ﬁrst  biochemical  abnormality  being
ed  cirrhosis  was  only  16  months.
upportive,  however  a  recombinant  protein  based  vaccine
as  been  found  to  be  safe  and  effective  in  phase  2  and  phase
 trials  in  China  [55].
hronic  hepatitis  in  the  immunocompetent
EV  chronicity  as  deﬁned  by  viral  persistence  for  at  least
 months  [5]  is  primarily  noted  in  patients  with  either
cquired  or  inherited  immunodeﬁciency.  Although  isolated
eports  of  immunocompetent  individuals  developing  chronic
EV  infection  have  been  described  [56,57]  an  antecedent
ometimes  occult  history  of  an  immunosuppressed  state  is
ften  noted  [57].
hronic hepatitis in the immunocompromised
ost
iven  the  rapidity  with  which  immunosuppressed  patients
ho  contract  chronic  HEV  may  develop  end-stage  liver
isease  it  is  imperative  to  consider  chronic  HEV  infection
n  those  with  evidence  of  liver  injury  (Fig.  3).  Once  infec-
ed  between  46  and  80%  of  solid  organ  transplant  recipients
re  ultimately  unable  to  spontaneously  clear  the  virus  and
re  thus  at  risk  of  chronicity  [10,44,58]; signiﬁcant  hepatic
brosis  can  develop  as  early  as  12  months  after  HEV  infection
44]. Immunosuppression,  iatrogenic  or  otherwise,  results  in
EV  persistence,  which  then  drives  iterative  bouts  of  hepatic
ecro-inﬂammation,  characterized  clinically  by  chronically
aised  ALT  activity  and  eventually  the  development  of  hepa-
ic  ﬁbrosis  and  cirrhosis.  Risk  factors  for  the  development
f  chronicity  in  solid  organ  transplant  recipients  include  the of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
se  of  tacrolimus  and  the  transplanted  organ  being  a  liver
53].
Chronic  HEV  infection  may  occur  in  any  immunocompro-
ised  patient  including  HIV  positive  patients  [53],  patients
ARTICLE IN PRESSModele +CLINRE-1232; No. of Pages 9
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Figure  4  HEV  infection  drives  the  development  of  acute  on  chronic  liver  failure  in  patients  with  established  cirrhosis.  A  54-
year-old male  who  was  active  on  the  liver  transplant  waiting  list  for  non-alcoholic  steatohepatitis  associated  cirrhosis  presented
with a  10-day  history  of  acute  decompensation  manifested  by  the  development  of  jaundice  and  worsening  ascites.  His  complicated
medical history  was  signiﬁcant  for  small  bowel  Crohn’s  disease;  and  he  had  recently  been  commenced  on  an  anti-TNFa  monoclonal
antibody (adalimumab;  Humira®)  and  prednisolone.  Testing  conﬁrmed  acute  HEV  G3  infection  with  HEV  detectable  in  both  blood  and
stool by  PCR.  In  contrast  to  the  non-cirrhotic  transplant  recipient  mentioned  above,  acute  HEV  infection  in  this  instance  resulted
in signiﬁcant  liver  dysfunction  exempliﬁed  by  coagulopathy,  jaundice  and  ascites.  The  patient  recompensated  with  ribavirin  and
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oxhibited a  SVR.  Stool  HEV  PCR  was  negative  at  3  and  6  months
ith  chronic  granulomatous  conditions  or  connective  tissue
isorders  like  SLE  [59]  and  as  illustrated  above,  immuno-
uppressed  organ  transplant  recipients  [53].  The  incubation
eriod  for  the  virus  in  the  context  of  immunosuppression  is
onger  than  seen  in  immunocompetent  hosts  at  60  days,  with
hronicity  itself  being  deﬁned  by  viral  persistence  after  the
cute  phase  for  either  3  or  6  months  [5].  Chronic  HEV  infec-
ion  in  immunocompromised  patients  is  almost  exclusively
econdary  to  HEV  G3  infection;  one  case  of  chronic  HEV  G4
nfection  has  been  noted  but  none  due  to  HEV  G1  or  G2  [5].
reatment  of  solid  organ  transplant  recipients
anagement  of  HEV  infection  in  immunosuppressed  solid
rgan  transplant  recipients  represents  a  unique  challenge.
ommonly  used  immunosuppressive  medications  for  solid
rgan  transplant  recipients  have  varying  effects  on  HEV
eplication,  calcineurin  inhibitors  such  as  tacrolimus  and
iclosporin  for  instance  have  been  shown  to  enhance  HEV
eplication  in  vitro  whilst  mycophenolate  mofetil  seems  to
nhibit  HEV  replication  [60].  Mechanistic  target  of  rapamy-
in  (mTOR)  inhibitors  may  perpetuate  HEV  infection  [61].
nterestingly  steroids  have  actually  been  noted  to  counte-
act  the  powerful  hepatic  necroinﬂammatory  response  that
EV  infection  can  occasionally  elicit,  whilst  simultaneously
llowing  for  viral  clearance  [62],  although  their  therapeutic
otential  role  is  unclear  (Fig.  3).
In  our  centre,  we  have  had  36  cases  of  serologically
onﬁrmed  chronic  HEV  in  solid  organ  transplant  recipients.
nitial  management  for  most  of  our  cases  was  a  reduction
n  immunosuppression.  Over  half  (55%—20  patients)  clea-
ed  HEV  infection  by  this  measure,  the  remainder  had  a
igniﬁcant  residual  viraemia  and  were  treated  with  ribavirinPour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
16  patients).  A  quarter  of  solid  organ  transplant  recipients
reated  at  our  centre  for  chronic  HEV  infection  exhibited
reatment  failure  and  thus  required  at  least  one  further
ourse  of  ribavirin;  in  all  of  these  patients  HEV  relapse  was
p
i
r
[ treatment.
oted  due  to  persistent  HEV  stool  shedding  at  three  months
nd  all  related  to  a  ribavirin  dose  reduction  (due  to  ribavirin
ide  effects)  (Fig.  4).
Consistent  with  our  practice,  the  BTS  and  EASL  guide-
ines  [36,37]  suggest  that  if  feasible  the  initial  treatment  for
EV  infection  in  solid  organ  transplant  recipients  should  be
 reduction  in  the  dose  of  immunosuppression;  this  measure
lears  HEV  infection  in  about  a  third  of  infected  patients
8].  Patients  that  present  with  severe  liver  dysfunction
coagulopathy,  jaundice  or  encephalopathy)  or  exhibit  viral
ersistence  as  evidenced  by  infection  lasting  greater  than
hree  months  despite  a  reduction  in  immunosuppression
eed  further  treatment  [36].  The  BTS  recommend  ribavirin
s  the  ﬁrst  line  agent  [36,63].  The  dose  needs  to  adjus-
ed  according  to  renal  function  and  haemoglobin  levels
EASL  guidelines),  dose  dependent  anaemia  remains  a  rela-
ive  contraindication  and  was  a  common  reason  for  therapy
essation  at  our  centre.  Once  started,  treatment  normally
asts  between  3  to  6  months;  negative  stool  samples  and
erum  viral  PCR  will  help  dictate  when  to  stop  treatment
s  continued  shedding  of  HEV  in  stool  is  an  important  fac-
or  in  predicting  relapse  after  ribavirin  treatment.  An  early
esponse  to  ribavirin  treatment  helps  predict  long-term
learance  and  can  be  used  to  guide  length  of  treatment
64]. Kamar  et  al  found  that  treatment  with  ribavirin  in  solid
rgan  transplant  recipients  at  a  median  dose  of  600  mg/day
or  three  months  resulted  in  an  SVR  of  78%,  the  majority  of
elapsers  attained  SVR  after  6  months  of  ribavirin  monothe-
apy  [37,63].  The  EASL  guidelines  thus  suggest  that  relapse
fter  3  months  of  ribavirin  therapy  should  be  treated  with
 longer  6-month  course  of  ribavirin.  In  cases  of  treatment
ailure,  as  gauged  by  viral  persistence  in  the  stools  or  serum
fter  completion  of  ribavirin  therapy,  EASL  suggest  a  trial
f  pegylated  interferon  for  3  months  in  liver  transplant  reci- of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
ients  [37]; pegylated  interferon  is  however  contraindicated
n  heart,  lung,  kidney  and  pancreas  recipients  due  to  the
elatively  greater  risk  of  ribavirin  triggered  acute  rejection
65].
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Acute  on  chronic  liver  failure
Acute  HEV  infection  in  patients  with  pre-existing  chronic
liver  disease  can  result  in  acute-on-chronic  liver  failure
(ACLF)  [66]  (Fig.  4).  The  infecting  HEV  genotype  appears
to  dictate  severity  or  degree  of  liver  injury  encountered  as
although  ACLF  has  been  described  with  HEV  G3  in  a  Euro-
pean  cohort  of  patients,  no  difference  in  patient  outcome
in  terms  of  mortality  compared  to  other  causes  of  ACLF  [67]
was  noted.  Contrastingly  studies  from  China  and  the  Indian
subcontinent  where  the  responsible  genotype  was  always
either  HEV  G1  or  G2  [66]  reveal  a  far  worse  outcome.  Compo-
site  mortality  was  reported  as  up  to  67%  with  a  median  of
34%  [66].  Shrestha  et  al  in  fact  report  that  over  a  ﬁfth  of
all  cases  of  ACLF  in  Asian  countries  are  due  to  acute  HEV
infection  [51].
Treatment
Acute  HEV  infection  in  patients  with  established  cirrhosis
can  result  in  the  development  of  ACLF.  The  BTS  suggest
the  early  use  of  ribavirin  in  patients  with  end  stage  liver
disease  awaiting  liver  transplantation  [36].  In  the  case  dis-
cussed  (Fig.  4)  ribavirin  cleared  HEV  infection  sufﬁciently  to
allow  hepatic  recompensation.
Extrahepatic  manifestations
Although  HEV  has  been  associated  with  a  variety  of  extra-
hepatic  syndromes,  a  causal  link  for  most  of  these  is  yet  to
be  established  [68]  (Fig.  5).  Acute  pancreatitis  in  patients
with  fulminant  viral  hepatitis  has  been  previously  been  des-
cribed,  but  this  is  mainly  in  patients  with  hepatitis  A,  B  or
C.  More  recently,  HEV  has  been  noted  to  cause  acute  pan-
creatitis  [69].  Most  reports  of  HEV  associated  pancreatitis
come  from  South  Asia  due  to  G1;  no  reports  of  G3  resulting
in  pancreatitis  have  been  described  [68].
Over  100  cases  describing  the  neurological  sequelae  of
HEV  infection  have  also  been  reported  [70].  The  neuro-
logical  injury  that  accompanies  HEV  infection  manifests
with  a  variety  of  symptomology  ranging  from  post-infectious
polyradiculoneuropathy  (Guillain—Barré  syndrome;  GBS)  to
neuralgic  amyotrophy  and  meningo-encephalitis  [70]. It
seems  likely  that  the  neurological  insult  in  GBS  and  neuralgic
amyotrophy  is  postinfectious  and  immune  mediated;  this  is
in  line  with  what  is  currently  known  about  the  pathophysio-
logy  of  these  conditions  [68,70].  HEV  meningo-encephalitis
is  in  contrast  thought  to  be  a  consequence  of  the  direct
neurotoxic  effect  of  the  virus  [70,71].  Deﬁnitive  causality  is
yet  to  be  established  in  either  of  these  neurological  condi-
tions  but  the  presence  of  HEV  RNA  in  the  CSF  of  patients
with  meningo-encephalitis  arguably  conﬁrms  the  neurotro-
pic  nature  of  the  virus  [68,72,73].
Both  acute  and  chronic  HEV  infection  are  also  associa-
ted  with  kidney  injury  [68].  The  causative  renal  pathology
is  variable  as  kidney  biopsies  of  patients  who  were
HEV  infected  and  presented  with  renal  abnormalitiesPour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
reveal  histological  features  of  membranous  glomerulone-
phritis,  membranoproliferative  glomerulonephritis  and  even
relapses  of  IgA  nephropathy  [68].  Aside  from  one  report  of
HEV  G1  causing  renal  dysfunction  the  majority  of  reported
t
t
d
eigure  5  Summary  of  extrahepatic  manifestations  of  HEV
nfection.
ases  of  HEV  driven  renal  dysfunction  are  due  to  HEV  G3  [71].
gain  deﬁnitive  causality  is  yet  to  be  established  but  HEV
learance  was  associated  with  normalization  of  renal  func-
ion  [68]. A  possible  mechanism  via  which  renal  dysfunction
ccurs  in  HEV  infected  patients  is  through  the  development
f  cryoglobulinaemia  [68,71].
reatment
omprehensive  data  accurately  deﬁning  management  of
xtrahepatic  HEV  are  currently  lacking  [68].  Anecdotal  evi-
ence  suggests  early  treatment  with  ribavirin  may  alter  the
atural  history  of  the  disease  [74]  and  thus  the  BTS  suggest
arly  treatment  with  ribavirin  be  initiated.
onclusion
nfection  with  HEV  remains  a  global  cause  of  mortality  and
orbidity.  The  last  10  years  have  resulted  in  a  far  greater
nderstanding  about  the  pathobiology  of  this  virus;  particu-
arly  relevant  to  the  western  populace  and  indeed  the  wider of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
ransplanted  community  is  the  propensity  for  HEV  infec-
ion  to  drive  rapid  liver  ﬁbrosis  and  thus  end  stage  liver
isease  in  the  immunosuppressed.  Prompt  recognition  and
arly  intervention  in  such  groups  of  patients  remains  key
 INModele +C
8
t
g
p
b
w
t
i
o
t
i
a
r
E
F
A
j
r
U
T
N
v
U
t
o
C
J
i
T
t
m
N
T
N
e
t
D
T
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[ARTICLELINRE-1232; No. of Pages 9
 
o  effective  management.  An  important  question  to  address
oing  forward  is  whether  vaccination  may  be  beneﬁcial  in
atients  where  HEV  infection  is  associated  with  particularly
ad  outcomes  such  as  the  immunosuppressed  or  patients
ith  chronic  liver  disease,  although  vaccines  for  HEV  are  in
rials;  the  efﬁcacy  of  vaccination  in  such  groups  of  patients
s  yet  to  be  established  [37].  Given  the  fact  that  the  risk
f  contracting  the  virus  is  greater  from  infected  foodstuff
han  even  infected  blood  transfusion  [14],  dietary  measures
ncluding  avoidance  of  undercooked  meat  and  shellﬁsh  in
t  risk  populations  such  as  immunosuppressed  transplant
ecipients  would  likely  be  beneﬁcial  in  reducing  hepatitis
 transmission  [37].
unding
lthough  no  speciﬁc  funding  was  received  for  this  pro-
ect,  AC  has  beneﬁtted  from  a  Wellcome  trust  clinical
esearch  training  fellowship  and  GJW  has  beneﬁtted  from
K  Medical  Research  Council  Clinical  Research  Fellowship.
his  paper  presents  independent  research  supported  by  the
IHR  Birmingham  Biomedical  Research  Centre  at  the  Uni-
ersity  Hospitals  Birmingham  NHS  Foundation  Trust  and  the
niversity  of  Birmingham.  The  views  expressed  are  those  of
he  author(s)  and  not  necessarily  those  of  the  NHS,  the  NIHR
r  the  Department  of  Health.
ontributions
F  originally  conceived  the  article  which  was  then  modiﬁed
n  response  to  suggestions  from  each  of  the  other  authors.
he  manuscript  was  written  by  AC.  All  authors  contribu-
ed  to  interpretation  of  the  results  and  approved  the  ﬁnal
anuscript.
IHR Disclaimer
his  report  presents  independent  research  funded  by  the
ational  Institute  for  Health  Research  (NIHR).  The  views
xpressed  are  those  of  the  authors(s)  and  not  necessarily
hose  of  the  NHS,  the  NIHR  or  the  Department  of  Health
isclosure of interest
he  authors  declare  that  they  have  no  competing  interest.
éférences
[1] Kamar N, et al. Hepatitis E. Lancet 2012;379:2477—88.
[2] Khuroo MS. Study of an epidemic of non-A, non-B hepatitis.
Possibility of another human hepatitis virus distinct from post-
transfusion non-A, non-B type. Am J Med 1980;68:818—24.
[3] Balayan MS, et al. Evidence for a virus in non-A, non-B
hepatitis transmitted via the fecal-oral route. Intervirology
1983;20:23—31.
[4] Chauhan A, et al. Hepatitis E virus transmission to a volunteer.Pour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
Lancet 1993;341:149—50.
[5] Donnelly MC, et al. Review article: hepatitis E-a concise review
of virology, epidemiology, clinical presentation and therapy.
Aliment Pharmacol Ther 2017;46:126—41.
[ PRESS
A.  Chauhan  et  al.
[6] Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and
fetal outcomes in pregnant women with acute hepatitis E virus
infection. Ann Intern Med 2007;147:28—33.
[7] Debing Y, Neyts J. Antiviral strategies for hepatitis E virus.
Antiviral Res 2014;102:106—18.
[8] Kamar N, et al. Inﬂuence of immunosuppressive therapy on the
natural history of genotype 3 hepatitis-E virus infection after
organ transplantation. Transplantation 2010;89:353—60.
[9] Peron JM. Hepatitis E virus infection and cirrhosis of the liver.
Gastroenterol Hepatol (N Y) 2016;12:565—7.
10] Kamar N, Rostaing L, Izopet J. Hepatitis E virus infection
in immunosuppressed patients: natural history and therapy.
Semin Liver Dis 2013;33:62—70.
11] Sayed IM, Vercouter A-S, Abdelwahab SF, Vercauteren K, Meule-
man P. Is hepatitis E virus an emerging problem in industrialized
countries? Hepatology 2015;62:1883—92.
12] Sridhar S, Teng JLL, Chiu TH, Lau SKP, Woo PCY. Hepatitis E
Virus genotypes and evolution: emergence of camel hepatitis
E variants. Int J Mol Sci 2017;18.
13] Vercouter AS, Meuleman P. Elucidating the differences in
pathogenicity between hepatitis E virus genotypes: the quest
continues. Hepatol Commun 2018;2:128—30.
14] Tedder RS, et al. Hepatitis E risks: pigs or blood-that is the
question. Transfusion 2017;57:267—72.
15] Scobie L, Dalton HR. Hepatitis E: source and route of infection,
clinical manifestations and new developments. J Viral Hepat
2013;20:1—11.
16] Wedemeyer H, Pischke S, Manns MP. Pathogenesis and
treatment of hepatitis e virus infection. Gastroenterology
2012;142:1388—97 [e1381].
17] Li TC, et al. Hepatitis E virus transmission from wild boar meat.
Emerg Infect Dis 2005;11:1958—60.
18] Hartl J, Wehmeyer MH, Pischke S. Acute hepatitis E: two  sides
of the same coin. Viruses 2016;8.
19] Lee GH, et al. Chronic infection with camelid hepatitis E virus
in a liver transplant recipient who regularly consumes camel
meat and milk. Gastroenterology 2016;150:355—7 [e353].
20] Adlhoch C, et al. Hepatitis E virus: assessment of the epide-
miological situation in humans in Europe, 2014/15. J Clin Virol
2016;82:9—16.
21] Bazerbachi F, Haffar S, Garg SK, Lake JR. Extra-hepatic
manifestations associated with hepatitis E virus infection: a
comprehensive review of the literature. Gastroenterol Rep
(Oxf) 2016;4:1—15.
22] Stanaway JD, et al. The global burden of viral hepatitis from
1990 to 2013: ﬁndings from the global burden of disease study
2013. Lancet 2016;388:1081—8.
23] Said B, et al. Hepatitis E outbreak on cruise ship. Emerg Infect
Dis 2009;15:1738—44.
24] Hartl J, et al. Hepatitis E seroprevalence in Europe: a meta-
analysis. Viruses 2016;8.
25] Mansuy JM, et al. A nationwide survey of hepatitis E
viral infection in French blood donors. Hepatology 2016;63:
1145—54.
26] Kuniholm MH, et al. Epidemiology of hepatitis E virus in the Uni-
ted States: results from the third national health and nutrition
examination survey, 1988-1994. J Infect Dis 2009;200:48—56.
27] Hewitt PE, et al. Hepatitis E virus in blood components: a
prevalence and transmission study in southeast England. The
Lancet 2014;384:1766—73.
28] Fearon MA, et al. Hepatitis E in Canadian blood donors. Trans-
fusion 2017;57:1420—5.
29] Haffar S, et al. Systematic review with meta-analysis: the asso-
ciation between hepatitis E seroprevalence and haemodialysis. of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
Aliment Pharmacol Ther 2017;46:790—9.
30] Faber M, et al. Hepatitis E virus seroprevalence, seroincidence
and seroreversion in the German adult population. J Viral
Hepat 2018;25:752—8.
 INModele +
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
transplant recipient. Dig Dis Sci 2013;58:2413—6.ARTICLECLINRE-1232; No. of Pages 9
Clinical  presentations  of  Hepatitis  E  
[31] Slot E, et al. Meat consumption is a major risk factor for hepa-
titis E virus infection. PLoS One 2017;12:e0176414.
[32] Meng XJ, et al. Prevalence of antibodies to hepatitis E virus in
veterinarians working with swine and in normal blood donors
in the United States and other countries. J Clin Microbiol
2002;40:117—22.
[33] Mughini-Gras L, et al. Hepatitis E virus infection in North Italy:
high seroprevalence in swine herds and increased risk for swine
workers. Epidemiol Infect 2017;145:3375—84.
[34] Yazaki Y, et al. Sporadic acute or fulminant hepatitis E in
Hokkaido, Japan, may be food-borne, as suggested by the pre-
sence of hepatitis E virus in pig liver as food. J Gen Virol
2003;84:2351—7.
[35] Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmis-
sion of hepatitis E virus from deer to human beings. Lancet
2003;362:371—3.
[36] McPherson S, et al. Summary of the British transplantation
society UK guidelines for hepatitis E and solid organ transplan-
tation. Transplantation 2018;102:15—20.
[37] European Association for the Study of the Liver. Electronic
address, e.e.e., European Association for the Study of the, L.
EASL Clinical Practice Guidelines on hepatitis E virus infection.
J Hepatol 2018;68:1256—71.
[38] Arends JE, et al. Hepatitis E: an emerging infection in high
income countries. J Clin Virol 2014;59:81—8.
[39] Aggarwal R. Diagnosis of hepatitis E. Nature reviews gastroen-
terology. Hepatology 2012;10:24—33.
[40] Drobeniuc J, et al. Serologic assays speciﬁc to immunoglobulin
M antibodies against hepatitis E virus: pangenotypic evaluation
of performances. Clin Infect Dis 2010;51:24—7.
[41] Wu WC, et al. Application of serologic assays for diagnosing
acute hepatitis E in national surveillance of a nonendemic area.
J Med Virol 2014;86:720—8.
[42] Sakiani S, Koh C, Heller T. Understanding the presence
of false-positive antibodies in acute hepatitis. J Infect Dis
2014;210:1886—9.
[43] Ghinoiu M, et al. Acute hepatitis E infection associated with
a false-positive serology against Epstein-Barr virus. Eur J Gas-
troenterol Hepatol 2009;21:1433—5.
[44] Kamar N, et al. Hepatitis E virus and chronic hepatitis in organ-
transplant recipients. N Engl J Med 2008;358:811—7.
[45] Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST.
The global burden of hepatitis E virus genotypes 1 and 2 in
2005. Hepatology 2012;55:988—97.
[46] Zhu FC, et al. Efﬁcacy and safety of a recombinant
hepatitis E vaccine in healthy adults: a large-scale, rando-
mised, double-blind placebo-controlled, phase 3 trial. Lancet
2010;376:895—902.
[47] Aherﬁ S, et al. Liver transplantation for acute liver failure rela-
ted to autochthonous genotype 3 hepatitis E virus infection.
Clin Res Hepatol Gastroenterol 2014;38:24—31.
[48] Carre M, et al. Fatal autochthonous fulminant hepatitis E early
after allogeneic stem cell transplantation. Bone Marrow Trans-
plant 2017;52:643—5.
[49] Dalton HR, et al. The role of hepatitis E virus tes-
ting in drug-induced liver injury. Aliment Pharmacol Ther
2007;26:1429—35.
[50] Dalton HR, Seghatchian J. Hepatitis E virus: emerging from
the shadows in developed countries. Transfus Apher SciPour  citer  cet  article  :  Chauhan  A,  et  al.  Clinical  presentations
histories.  Clin  Res  Hepatol  Gastroenterol  (2019),  https://doi.o
2016;55:271—4.
[51] Shrestha A. Current treatment of acute and chronic hepatitis e
virus infection: role of antivirals. Euroasian J Hepatogastroen-
terol 2017;7:73—7. B, P.G., T, K.L.
[ PRESS
9
52] Gerolami R, et al. Treatment of severe acute hepatitis E by
ribavirin. J Clin Virol 2011;52:60—2.
53] Kamar N, et al. Factors associated with chronic hepatitis in
patients with hepatitis E virus infection who have received solid
organ transplants. Gastroenterology 2011;140:1481—9.
54] Tjwa E, Munsterman I, Drenth J. Treatment of hepatitis E
infection in immuno-incompetent patients: reduction of immu-
nosuppression appears to be more effective than ribavirin
therapy. J Hepatol 2017;66:S331.
55] Perez-Gracia MT, Suay-Garcia B, Mateos-Lindemann ML. Hepa-
titis E and pregnancy: current state. Rev Med Virol 2017.
56] Pischke S, et al. Ribavirin treatment of acute and chronic hepa-
titis E: a single-centre experience. Liver Int 2013;33:722—6.
57] Grewal P, Kamili S, Motamed D. Chronic hepatitis E in
an immunocompetent patient: a case report. Hepatology
2014;59:347—8.
58] Moal V, et al. Infection with hepatitis E virus in kidney
transplant recipients in southeastern France. J Med Virol
2013;85:462—71.
59] Honer zu Siederdissen C, et al. Chronic hepatitis E virus infec-
tion beyond transplantation or human immunodeﬁciency virus
infection. Hepatology 2014;60:1112—3.
60] Wang Y, et al. Calcineurin inhibitors stimulate and myco-
phenolic acid inhibits replication of hepatitis E virus.
Gastroenterology 2014;146:1775—83.
61] Zhou X, et al. Rapamycin and everolimus facilitate hepatitis
E virus replication: revealing a basal defense mechanism of
PI3K-PKB-mTOR pathway. J Hepatol 2014;61:746—54.
62] Sebode M, et al. New foe treated with old guns - supportive
role of steroids in the treatment of acute severe hepatitis E.
BMC Gastroenterol 2014;14:191.
63] Kamar N, et al. Ribavirin for chronic hepatitis E virus infection
in transplant recipients. N Engl J Med 2014;370:1111—20.
64] Kamar N, et al. An early viral response predicts the virologi-
cal response to ribavirin in hepatitis E virus organ transplant
patients. Transplantation 2015;99:2124—31.
65] Rostaing L, et al. Treatment of chronic hepatitis C with
recombinant interferon alpha in kidney transplant recipients.
Transplantation 1995;59:1426—31.
66] Kumar A, Saraswat VA, Hepatitis E. Acute-on-chronic liver fai-
lure. J Clin Exp Hepatol 2013;3:225—30.
67] Blasco-Perrin H, et al. Hepatitis E virus in patients with decom-
pensated chronic liver disease: a prospective UK/French study.
Aliment Pharmacol Ther 2015;42:574—81.
68] Kamar N, Marion O, Abravanel F, Izopet J, Dalton HR.
Extrahepatic manifestations of hepatitis E virus. Liver Int
2016;36:467—72.
69] Mishra A, Saigal S, Gupta R, Sarin SK. Acute pancreatitis asso-
ciated with viral hepatitis: a report of six cases with review of
literature. Am J Gastroenterol 1999;94:2292—5.
70] Dalton HR, et al. Hepatitis E virus and neurological injury. Nat
Rev Neurol 2016;12:77—85.
71] Pischke S, et al. Hepatitis E virus: Infection beyond the liver? J
Hepatol 2017;66:1082—95.
72] Despierres LA, et al. Neurologic disorders and hepatitis E,
France, 2010. Emerg Infect Dis 2011;17:1510—2.
73] Maddukuri VC, et al. Chronic hepatitis E with neurologic mani-
festations and rapid progression of liver ﬁbrosis in a liver of  Hepatitis  E:  A  clinical  review  with  representative  case
rg/10.1016/j.clinre.2019.01.005
74] Perrin HB, et al. Neurologic disorders in immunocompetent
patients with autochthonous acute hepatitis E. Emerg Infect
Dis 2015;21:1928—34.
